annonce TG4050en

Clinical Proof of Principlein head and neck cancer All treated patients remain disease-free after a median follow up of 24.1 months   Press release [PDF] Poster presented at SITC 2024 Listen to Dr. Alessandro Riva’s comments, Chairman & CEO of Transgene  (VOST) Liste to the KOL Event TG4050 (April, 2023) (in English) One cancer, one… Continue reading annonce TG4050en

annonceHomeUS

TG4050First positive data from Phase I clinical trials Press release [PDF] Initial data presented at the ASCO congress (June 2022) Interview of the team and Pr Ottensmeier on the data (November 2022)

annonce substitut

A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor. TG4050 video

annonce

One cancer, one patient, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies. The treatment is based on an optimized MVA viral vector. myvac® video Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens)… Continue reading annonce

produits : BT-001

  BT-001 BT-001 is a multifunctional oncolytic virus from Invir.IO® platform. Two specific “weapons” have been integrated into the vaccinia viral DNA: an anti-CTLA4 antibody , which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response. Selectively destroying cancer cells   Discover how BT-001 works * requires analytics cookies Derived… Continue reading produits : BT-001

teaserproduits : BT-001

BT-001 is an armed oncolytic virus expressing an anti-CTLA4 and GM-CSF antibody, from the Invir.IO® platform. It has been evaluated in a Phase 1/2a multicenter, open label, dose-escalation study as a single agent and in combination with pembrolizumab* in solid tumors after intratumoral administration. *KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC,… Continue reading teaserproduits : BT-001

FAQ patients

What is a clinical trial? Clinical trials are designed to evaluate new treatments, including their safety and efficacy. They are mandatory before approval and commercialization of new treatments. Who can participate in a clinical trial? Each clinical trial is conducted according to a protocol defined upstream and validated by the health authorities and various committees… Continue reading FAQ patients

teaser produits : TG4050

TG4050 is an Individualized Neoantigen Therapeutic Vaccine and the first asset from myvac® platform. It is being evaluated in a randomized multicenter Phase 1/2 clinical trial as a single agent in the adjuvant treatment of HPV-negative Head & Neck Squamous Cell Carcinoma (HNSCC). More information on clinicaltrial.gov TG4050 NCT04183166 A collaboration with Read more about… Continue reading teaser produits : TG4050

pipeline

Product Indication Collaboration Discovery Phase I Phase II INDIVIDUALIZED NEOANTIGEN CANCER VACCINES TG4050 Head and neck cancers (adjuvant) Other indication SHARED ANTIGENS CANCER VACCINES TG4001   Anogenital HPV+ cancers   Internal Shared driver mutations       ONCOLYTIC VIRUSES (OV) TG6050 Lung cancer (IV*)     BT-001 Solid tumors (IT*)   Internal   Synthetic OV… Continue reading pipeline